Director, Media Strategy and Execution

BioMarin is a leading rare disease biotechnology company focused on genetically defined conditions. Guided by our purpose to develop medicines that make a profound impact on people’s lives, our global teams have delivered a portfolio of therapies since our founding in 1997. Our revolutionary treatments for conditions like achondroplasia (the most common form of dwarfism), PKU (phenylketonuria), CLN2, a form of Batten disease, and a number of forms of MPS (mucopolysaccharidosis) offer new possibilities for patients and families who previously had few, if any, available options. More recently, with the close of the Amicus acquisition, our portfolio has expanded to include therapies for Fabry disease and Pompe disease, expanding our ability to reach more people living with rare genetic conditions. Our success comes from our unwavering commitment to excellence, our deep understanding of patient needs, our scientific expertise, and our world-class manufacturing capabilities. At the heart of BioMarin is a dedicated team of the brightest minds in the industry working together to deliver innovative therapies to patients and families around the world. About Commercial Be part of the worldwide infrastructure that gets our drugs to underserved patients around the world. Our global sales force solidifies BioMarin’s commercial presence in the United States and Europe and is rapidly growing in other regions, such as South America, EuMEA, and Asia-Pacific.

Summary The Director, Media Strategy and Execution will lead the development and execution of media plans that support brand ambitions across BioMarin’s Metabolic Conditions Business Unit. This role will centralize media expertise across a complex rare disease portfolio, ensuring media strategy, investment, activation, optimization, and measurement are tightly connected to brand objectives, patient and HCP audience needs, business priorities, and performance outcomes. The Director will serve as a strategic partner to brand teams, agencies and cross-functional leaders, bringing discipline, innovation, and accountability to how BioMarin plans and activates paid media across HCP, patient, caregiver, and related healthcare audiences. The successful candidate will combine rare disease marketing judgment, strong media fluency, agency leadership, financial discipline, and the ability to translate data into clear decisions that improve customer engagement and business impact. This role will report directly to the Head of Marketing, US Metabolic Conditions. Key Responsibilities •    Lead portfolio-level media strategy across the U.S. Metabolic Conditions Business Unit, including 5 disease states, plus any additional as the business unit grows. •    Partner with media agency to develop annual, quarterly, and in-cycle media plans that translate brand strategies, audience insights, market dynamics, and business objectives into clear media priorities, channel roles, tactical recommendations, and investment plans. •    Partner with brand teams to define what media must accomplish for each brand, including awareness, education, diagnosis, treatment consideration, patient finding, switching, retention, adherence, and customer engagement objectives. •    Drive integrated HCP and patient/caregiver media planning across channels such as paid search, paid social, programmatic, endemic and non-endemic media, video/CTV, digital partnerships, emerging platforms, and other priority media opportunities. •    Ensure media plans are grounded in rare disease audience realities, including small patient populations, high-intent moments, complex treatment journeys, HCP specialty dynamics, caregiver roles, and compliant use of data and targeting capabilities. •    Lead media budget planning, allocation, scenario development, and funding tradeoff recommendations across brands, audiences, campaigns, and vendors. •    Oversee agency partners across media strategy, planning,